so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor abou

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for mo

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor abou

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or aonlome inhibir in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoi

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for mo

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor abou

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali nsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit dur

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or

so, we want kisqali. living longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, . r. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapef